Cargando…
Efficacy and Microbiota Modulation Induced by LimpiAL 2.5%, a New Medical Device for the Inverse Psoriasis Treatment
(1) Inverse psoriasis (IP), also known as intertriginous, typically affects the groin, armpits, navel, intergluteal fissure, and external genitalia. Skin lesions are erythematous plaques of inflammatory nature, smooth, well-delimited, non-scaly, and non-infiltrated. Lesions may be accompanied by itc...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094358/ https://www.ncbi.nlm.nih.gov/pubmed/37047310 http://dx.doi.org/10.3390/ijms24076339 |
_version_ | 1785023822694449152 |
---|---|
author | Pietrangelo, Laura Dattola, Annunziata Magnifico, Irene Petronio Petronio, Giulio Cutuli, Marco Alfio Venditti, Noemi Guarnieri, Antonio Wollenberg, Andreas Pellacani, Giovanni Di Marco, Roberto |
author_facet | Pietrangelo, Laura Dattola, Annunziata Magnifico, Irene Petronio Petronio, Giulio Cutuli, Marco Alfio Venditti, Noemi Guarnieri, Antonio Wollenberg, Andreas Pellacani, Giovanni Di Marco, Roberto |
author_sort | Pietrangelo, Laura |
collection | PubMed |
description | (1) Inverse psoriasis (IP), also known as intertriginous, typically affects the groin, armpits, navel, intergluteal fissure, and external genitalia. Skin lesions are erythematous plaques of inflammatory nature, smooth, well-delimited, non-scaly, and non-infiltrated. Lesions may be accompanied by itching, pain, or burning sensation. The aim of this study is both to investigate the modulation of the skin microbiota induced by IP and, on the other hand, to test the effectiveness of the new biotechnological product LimpiAL 2.5%. (2) Patients affected by IP were recruited in a private practice and treated for 4 weeks with LimpiAL 2.5% exclusively. The clinical effects on the lesion skin were evaluated, and the skin microbiotas before and after treatment were compared. (3) The clinical outcomes reveled a significant beneficial effect of the tested product. At the same time, LimpiAL increased the biological diversity of the skin microbiota and exerted a significant decrease of some Corynebacterium species, and the increase of some Staphylococcus species. (4) Together, the clinical outcomes and the microbiota analysis suggest that LimpiAL treatment improves the skin condition of affected patients, basically restoring the eubiosis conditions of the affected sites and modulating the bacterial composition of the resident microbiota. |
format | Online Article Text |
id | pubmed-10094358 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100943582023-04-13 Efficacy and Microbiota Modulation Induced by LimpiAL 2.5%, a New Medical Device for the Inverse Psoriasis Treatment Pietrangelo, Laura Dattola, Annunziata Magnifico, Irene Petronio Petronio, Giulio Cutuli, Marco Alfio Venditti, Noemi Guarnieri, Antonio Wollenberg, Andreas Pellacani, Giovanni Di Marco, Roberto Int J Mol Sci Article (1) Inverse psoriasis (IP), also known as intertriginous, typically affects the groin, armpits, navel, intergluteal fissure, and external genitalia. Skin lesions are erythematous plaques of inflammatory nature, smooth, well-delimited, non-scaly, and non-infiltrated. Lesions may be accompanied by itching, pain, or burning sensation. The aim of this study is both to investigate the modulation of the skin microbiota induced by IP and, on the other hand, to test the effectiveness of the new biotechnological product LimpiAL 2.5%. (2) Patients affected by IP were recruited in a private practice and treated for 4 weeks with LimpiAL 2.5% exclusively. The clinical effects on the lesion skin were evaluated, and the skin microbiotas before and after treatment were compared. (3) The clinical outcomes reveled a significant beneficial effect of the tested product. At the same time, LimpiAL increased the biological diversity of the skin microbiota and exerted a significant decrease of some Corynebacterium species, and the increase of some Staphylococcus species. (4) Together, the clinical outcomes and the microbiota analysis suggest that LimpiAL treatment improves the skin condition of affected patients, basically restoring the eubiosis conditions of the affected sites and modulating the bacterial composition of the resident microbiota. MDPI 2023-03-28 /pmc/articles/PMC10094358/ /pubmed/37047310 http://dx.doi.org/10.3390/ijms24076339 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Pietrangelo, Laura Dattola, Annunziata Magnifico, Irene Petronio Petronio, Giulio Cutuli, Marco Alfio Venditti, Noemi Guarnieri, Antonio Wollenberg, Andreas Pellacani, Giovanni Di Marco, Roberto Efficacy and Microbiota Modulation Induced by LimpiAL 2.5%, a New Medical Device for the Inverse Psoriasis Treatment |
title | Efficacy and Microbiota Modulation Induced by LimpiAL 2.5%, a New Medical Device for the Inverse Psoriasis Treatment |
title_full | Efficacy and Microbiota Modulation Induced by LimpiAL 2.5%, a New Medical Device for the Inverse Psoriasis Treatment |
title_fullStr | Efficacy and Microbiota Modulation Induced by LimpiAL 2.5%, a New Medical Device for the Inverse Psoriasis Treatment |
title_full_unstemmed | Efficacy and Microbiota Modulation Induced by LimpiAL 2.5%, a New Medical Device for the Inverse Psoriasis Treatment |
title_short | Efficacy and Microbiota Modulation Induced by LimpiAL 2.5%, a New Medical Device for the Inverse Psoriasis Treatment |
title_sort | efficacy and microbiota modulation induced by limpial 2.5%, a new medical device for the inverse psoriasis treatment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094358/ https://www.ncbi.nlm.nih.gov/pubmed/37047310 http://dx.doi.org/10.3390/ijms24076339 |
work_keys_str_mv | AT pietrangelolaura efficacyandmicrobiotamodulationinducedbylimpial25anewmedicaldevicefortheinversepsoriasistreatment AT dattolaannunziata efficacyandmicrobiotamodulationinducedbylimpial25anewmedicaldevicefortheinversepsoriasistreatment AT magnificoirene efficacyandmicrobiotamodulationinducedbylimpial25anewmedicaldevicefortheinversepsoriasistreatment AT petroniopetroniogiulio efficacyandmicrobiotamodulationinducedbylimpial25anewmedicaldevicefortheinversepsoriasistreatment AT cutulimarcoalfio efficacyandmicrobiotamodulationinducedbylimpial25anewmedicaldevicefortheinversepsoriasistreatment AT vendittinoemi efficacyandmicrobiotamodulationinducedbylimpial25anewmedicaldevicefortheinversepsoriasistreatment AT guarnieriantonio efficacyandmicrobiotamodulationinducedbylimpial25anewmedicaldevicefortheinversepsoriasistreatment AT wollenbergandreas efficacyandmicrobiotamodulationinducedbylimpial25anewmedicaldevicefortheinversepsoriasistreatment AT pellacanigiovanni efficacyandmicrobiotamodulationinducedbylimpial25anewmedicaldevicefortheinversepsoriasistreatment AT dimarcoroberto efficacyandmicrobiotamodulationinducedbylimpial25anewmedicaldevicefortheinversepsoriasistreatment |